BioCryst’s Orladeyo Pediatric Approval and Strategic Expansion Drive Buy Rating

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on BioCryst. The associated price target was raised to $32.00.

Andrew Fein has given his Buy rating due to a combination of factors surrounding BioCryst’s recent developments. The approval of Orladeyo for pediatric patients marks a significant milestone, as it is the first oral prophylactic therapy for children aged two to under twelve with hereditary angioedema (HAE). This approval addresses a critical gap in treatment options, which previously relied on painful intravenous or subcutaneous injections. By offering a more convenient oral option, BioCryst is expected to strengthen its HAE portfolio and potentially secure long-term revenue stability as patients could start treatment at a young age and continue into adulthood.
Moreover, the pediatric segment is seen as a vital growth opportunity, with Orladeyo anticipated to become the leading prophylactic treatment for young patients in the U.S. The launch is expected to benefit from a “halo” effect, as adult prescribers familiar with Orladeyo may also treat pediatric patients, facilitating a smoother market introduction. Additionally, BioCryst’s strategic expansion into global markets and the acquisition of navenibart are expected to bolster its presence in the prophylactic HAE treatment space, ensuring both near-term and long-term growth while mitigating competitive risks. These factors collectively support Fein’s optimistic outlook and the raised price target of $32.

In another report released on December 12, Wedbush also maintained a Buy rating on the stock with a $21.00 price target.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year.